NCT05845398View on ClinicalTrials.gov

Phase 1b Study of DCR-AUD in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 29, 2023

Primary Completion Date

August 22, 2023

Study Completion Date

August 22, 2023

Conditions
Alcohol Use Disorder
Interventions
DRUG

DCR-AUD

DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and update after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).

DRUG

Placebo

0.9% saline for injection.

Trial Locations (1)

91206

Parexel Los Angeles Early Phase Clinical Unit, Glendale

All Listed Sponsors
lead

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

INDUSTRY